Naloxonazine Dihydrochloride

Potent opioid antagonist, selective for μ1 receptors.

Naloxonazine is a potent and selective μ-opioid receptor (MOR) antagonist, particularly targeting the μ1 receptor subtype. Unlike naloxone, which is a reversible and short-acting opioid antagonist, naloxonazine exhibits irreversible and long-lasting antagonistic effects on MORs. This irreversible binding is due to its ability to form covalent bonds with the receptor, leading to sustained inhibition even after the compound has been cleared from the system. In vivo studies have demonstrated that naloxonazine can antagonize morphine-induced analgesia for over 24 hours, with a terminal elimination half-life of less than 3 hours, indicating that its prolonged action is not solely due to its presence in the system but also due to its persistent receptor binding PubMed.

Additionally, naloxonazine has been found to have activity beyond opioid receptor antagonism. Research indicates that it affects intracellular Leishmania donovani, a parasitic protozoan, by modulating host cell functions. Specifically, naloxonazine treatment leads to the upregulation of vacuolar ATPases (vATPases) in THP-1 macrophages, resulting in an increased volume of intracellular acidic vacuoles. This suggests a host cell-dependent mechanism of action against the parasite PLOS.

In summary, naloxonazine serves as a valuable pharmacological tool for studying μ1-opioid receptor functions due to its irreversible and selective antagonistic properties. Its unique mechanism of action also presents potential therapeutic avenues beyond opioid receptor antagonism, such as in the treatment of intracellular parasitic infections.

Here are a more detailed summary of some analogs / related irreversible (or long-acting) μ-opioid antagonists (and tools) including potency data, in vivo/in vitro comparisons. Some of this is inferred from literature; absolute IC₅₀ data is rather limited and variable by assay type.

Key Analogs / Related Compounds

Comparative Data: Naloxonazine vs β-Funaltrexamine

Here are more detailed numbers from one key comparative study (Cotzias Lab, Sloan-Kettering) for Naloxonazine vs β-FNA: PubMed

Additional Notes & Context

• The distinction between μ₁ vs μ₂ opioid receptor subtypes is operationally defined by sensitivity to Naloxonazine. Naloxonazine sensitive actions are considered μ₁-mediated. Europe PMC+1

• For some behavioral effects (e.g. morphine conditioned place preference, reward), Naloxonazine has been used to show selectivity; however, its potency can be quite different across different endpoints. PubMed+1

• The wash-resistance or irreversibility depends on dose and site (supraspinal vs spinal, central vs peripheral). For example, Naloxonazine is less effective at spinal sites vs β-FNA. PubMed

0°C (short term), -20°C (long term), desiccated

1) Mhatre, M., and Holloway, F. μ1-opioid antagonist naloxonazine alters ethanol discrimination and consumption. Alcohol 29(2), 109-116 (2003).

2) Rademacher, D.J., and Steinpreis, R.E. Effects of the selective μ1-opioid receptor antagonist, naloxonazine, on cocaine-induced conditioned place preference and locomotor behavior in rats. Neurosci. Lett. 332(3), 159-162 (2002).